Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acebutolol
Drug ID BADD_D00019
Description A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Indications and Usage For the management of hypertension and ventricular premature beats in adults.
Marketing Status approved; investigational
ATC Code C07AB04
DrugBank ID DB01193
KEGG ID D02338
MeSH ID D000070
PubChem ID 1978
TTD Drug ID D0HD9K
NDC Product Code Not Available
UNII 67P356D8GH
Synonyms Acebutolol | Acetobutolol | Acebutolol Hydrochloride | M&B-17803 A | M&B 17803 A | M&B17803 A | M & B 17803A | Neptal | Prent | Rhotral | Sectral | Monitan | Apo-Acebutolol | Apo Acebutolol | ApoAcebutolol | Novo-Acebutolol | Novo Acebutolol | NovoAcebutolol
Chemical Information
Molecular Formula C18H28N2O4
CAS Registry Number 37517-30-9
SMILES CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus10.04.03.004; 23.03.02.006; 15.06.02.003--Not Available
Tachycardia02.03.02.007--Not Available
Therapeutic response decreased08.06.01.016--Not Available
Therapeutic response unexpected08.06.01.001--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Xerosis08.01.03.016--Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene